Abstract:The activity of HIV-1 and its viral proteins within the central nervous system (CNS) is responsible for a wide array of neuropathological effects, resulting in a spectrum of neurocognitive deficits defined as HIV-associated neurocognitive disorders (HAND). Amongst the various viral proteins, the transactivator of transcription (Tat) remains detectable even with effective antiretroviral therapy (ART) and suppressed viremia, highlighting the significance of this protein in the modern ART era. Tat has been extensively researched in both fundamental and clinical settings due to its role in neuroinflammation, neuronal damage, and neurocognitive impairment amongst people living with HIV (PLHIV). To date, numerous fundamental studies have explored Tat-induced neuroinflammation. However, there is no clear consensus on the most frequently studied inflammatory markers or the consistency in the levels of these Tat-induced inflammatory marker levels across different studies. Therefore, we conducted a scoping review of studies investigating Tat-induced neuroinflammation. We conducted searches in PubMed, Scopus, and Web of Science databases using a search protocol tailored specifically to adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for scoping reviews (PRISMA-ScR) guidelines. From the 22 included studies, findings suggest that the HIV-1 Tat protein amplifies levels of neuroinflammatory markers. Amongst the vast array of inflammatory markers explored in the included studies, consistent results point to higher levels of CCL2, IL-6, IL-8, and TNF-α in primary cells and cell lines exposed to or transfected with HIV-1 Tat. These markers are regulated by key inflammatory pathways, such as the extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) pathway, the phosphatidylinositol 3-kinase (PI3K) pathway, the p38 MAPK pathway, and nuclear factor-kB (NF-kB). Furthermore, Tat has been shown to induce neuronal apoptosis, both directly and indirectly. With regards to study designs, utilizing full-length Tat101 at concentrations ranging from 100 to 1000 ng/ml and durations of 24 and 48 h appears optimal for investigating Tat-induced neuroinflammation. In this context, we highlight specific inflammatory markers and pathways that are potentially pivotal in Tat-induced neuroinflammation and subsequent neuronal damage. A deeper investigation into these markers and pathways is crucial to better understand their roles in the development of HAND.

HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations

Acute Administration of HIV-1 Tat Protein Drives Glutamatergic Alterations in a Rodent Model of HIV-Associated Neurocognitive Disorders

HIV‐1 Inhibits Long‐term Potentiation and Attenuates Spatial Learning

Short‐term exposure to HIV Tat induces glial activation and changes in perineuronal nets

HIV-1 Tat enhances purinergic P2Y4 receptor signaling to mediate inflammatory cytokine production and neuronal damage via PI3K/Akt and ERK MAPK pathways

Neurovirulent and non-neurovirulent strains of HIV-1 and their Tat proteins induce differential cytokine-chemokine profiles

HIV-1 Tat Inhibits EAAT-2 Through AEG-1 Upregulation in Models of HIV-associated Neurocognitive Disorder

Neuropathogenic role of astrocyte‐derived extracellular vesicles in HIV‐associated neurocognitive disorders

Neuropathologies in Transgenic Mice Expressing Human Immunodeficiency Virus Type 1 Tat Protein under the Regulation of the Astrocyte-Specific Glial Fibrillary Acidic Protein Promoter and Doxycycline.

Tat 101-Mediated Enhancement of Brain Pericyte Migration Involves Platelet-Derived Growth Factor Subunit B Homodimer: Implications for Human Immunodeficiency Virus-Associated Neurocognitive Disorders

Transactivator of Transcription (Tat)-Induced Neuroinflammation as a Key Pathway in Neuronal Dysfunction: A Scoping Review

Soluble Hiv-1 Infected Macrophage Secretory Products Mediate Blockade Of Long-Term Potentiation: A Mechanism For Cognitive Dysfunction In Hiv-1-Associated Dementia

HIV Tat 101-mediated loss of pericytes at the blood-brain barrier involves PDGF-BB

HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-kappa B-YY1 Pathway

Glutaminase Dysregulation in Hiv-1-Infected Human Microglia Mediates Neurotoxicity: Relevant to Hiv-1-Associated Neurocognitive Disorders

Hiv-1 Tat Co-Operates With Ifn-Gamma And Tnf-Alpha To Increase Cxcl10 In Human Astrocytes

Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products

HIV-1 Infected and Immune Competent Mononuclear Phagocytes Induce Quantitative Alterations in Neuronal Dendritic Arbor: Relevance for HIV-1-associated Dementia.

Inhibition of long-term potentiation by interleukin-8: implications for human immunodeficiency virus-1-associated dementia.

Doxycycline-inducible and Astrocyte-Specific HIV-1 Tat Transgenic Mice (itat) As an HIV/neuroAIDS Model

Inhibitory Neurotransmission Is Sex-Dependently Affected by Tat Expression in Transgenic Mice and Suppressed by the Fatty Acid Amide Hydrolase Enzyme Inhibitor PF3845 via Cannabinoid Type-1 Receptor Mechanisms